Vantage logo

Big caps bounce back for biopharma

Months of share price declines made 2022 a year to forget for many, but large-caps staged a big recovery in the fourth quarter.

Vantage logo

Biotech’s near-term key catalysts

Important data reveals are expected from Madrigal, Arrowhead and Ascendis, with details from Biogen and Eisai due at a conference.